A possible limitation of our study is that patients were allocated by the surgeon to segmental or extended surgery groups based on clinical criteria (age at CRC diagnosis, localization of the tumor, existence of synchronous cancer, patient’s preference, etc.)without information regarding LS condition, MMR protein expression or BRAF mutation in tumor. The gene discussed is BRAF; the disease is colorectal carcinoma.